Santhera gibt Ausgründung seiner Graffinity Drug Discovery Technologie Geschaeftseinheit bekannt
January 03, 2006 02:00 ET
|
Santhera Pharmaceuticals Holding AG
Heidelberg, Deutschland und Liestal, Schweiz, 3. Januar 2006 - Santhera Pharmaceuticals AG ("Santhera"), ein auf neuromuskuläre Erkrankungen spezialisiertes Schweizer Biotechnologieunternehmen, gab...
Santhera Announces Management Buy-Out of the Graffinity Drug Discovery Technology Business
January 03, 2006 02:00 ET
|
Santhera Pharmaceuticals Holding AG
Heidelberg, Germany and Liestal, Switzerland - January 3, 2006 -- Santhera Pharmaceuticals AG, a Swiss-based specialty pharmaceutical company with a focus on neuromuscular diseases, announced today...
Santhera Raises CHF 25 Million (Euro 16 Million) Via a Further Closing of its 2005 B Financing Round
December 20, 2005 02:00 ET
|
Santhera Pharmaceuticals Holding AG
For release content, please refer to the attachment....
Santhera and the NIH Collaborate to Evaluate SNT-MC17 in Friedreich's Ataxia
November 02, 2005 02:00 ET
|
Santhera Pharmaceuticals Holding AG
...
Santhera Targets New Indication with its Lead Compound
October 19, 2005 02:00 ET
|
Santhera Pharmaceuticals Holding AG
...
Santhera Presents at the International Congress of Myology
May 07, 2005 02:00 ET
|
Santhera Pharmaceuticals Holding AG
...